Form 4: Aurinia Pharmaceuticals Director Acquires Shares and Stock Options

Aurinia Pharmaceuticals director Jeffrey Allen Bailey acquired 12,135 common shares and 18,641 stock options on November 21, 2024.

Summary

• On November 21, 2024, Jeffrey Allen Bailey, a director at Aurinia Pharmaceuticals, acquired 12,135 common shares through a grant of Restricted Stock Units (RSUs).
• These RSUs will vest one year from the grant date.
• Bailey also acquired 18,641 stock options with an exercise price of $8.24 per share.
• These options will also vest one year from the grant date and expire on November 21, 2034.
• Following these transactions, Bailey directly owns 25,491 common shares and 18,641 stock options.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment as it shows a director increasing their stake in the company, which is generally seen as a good sign. However, it is a routine filing and not a major event.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future prospects.
• The vesting period of one year for both the RSUs and stock options aligns the director's interests with the long-term performance of the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• The granting of stock options and restricted stock units to directors is a common practice in the pharmaceutical industry to incentivize performance and align interests with shareholders.
• The vesting period of one year is also typical for such grants.
• The exercise price of $8.24 for the stock options is a specific detail related to this particular grant and would need to be compared to other grants within Aurinia and its peers to assess its relative value.

Stakeholder Impact

• The transaction may have a slightly positive impact on shareholder sentiment as it indicates a director's confidence in the company.

Key Dates

Keywords

Aurinia Pharmaceuticals, Director, Stock Options, Restricted Stock Units, Share Acquisition, Insider Trading, Equity Compensation